Reuters logo
BRIEF-Akcea initiates phase 2 study of Akcea-APO(a)-l RX in patients with high LP(a) and cardiovascular disease
March 30, 2017 / 11:11 AM / 8 months ago

BRIEF-Akcea initiates phase 2 study of Akcea-APO(a)-l RX in patients with high LP(a) and cardiovascular disease

March 30 (Reuters) - Ionis Pharmaceuticals Inc

* Akcea initiates phase 2 study of Akcea-APO(a)-l RX in patients with high LP(a) and cardiovascular disease

* Akcea Therapeutics - plans to report top-line data from this study in middle of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below